Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Palatin Technologies and King Pharmaceuticals have begun enrolling patients into a phase IIb clinical trial of their development candidate PT-141 in patients with female sexual arousal disorder.
Subscribe to our email newsletter
The clinical trial, which will enroll approximately 60 patients, is designed to evaluate the safety and efficacy of PT-141 in the “at-home” environment. It will entail a two month treatment period and will be conducted at approximately ten clinical trial sites throughout the US.
PT-141 is the first compound in a new drug class called melanocortin receptor agonists under development to treat sexual dysfunction. The drug is also undergoing phase II trials evaluating it for the treatment of men experiencing erectile dysfunction.
“The data we gather from this study should prove significant for purposes of determining the future course of development for PT-141 in the treatment of female sexual dysfunction,” said Dr Trevor Hallam, executive vice president, R&D of Palatin.